Science
Intellectual Property
Global Licensing
A new model for turning science into value.
Most scientific discoveries never reach the market. Not for lack of scientific merit, but because few technologies complete the full journey needed to become pharmaceutical assets attractive to industry.
The Aether Platform was created to fill that gap, connecting research, development, intellectual property, capital, and market strategy in a structured value-creation model.
(our values)
Three principles guide every decision.
Science
We select research with high therapeutic potential and lead its development with technical rigor, translational vision, and a focus on industrial application.
Intellectual Property
We turn scientific knowledge into pharmaceutical assets through technological development, de-risking, and an integrated intellectual property strategy.
Global Licensing
We position assets for connection with the pharmaceutical industry, investors, and strategic partners, expanding their potential for technology transfer and commercialization.
Frontier science generates discoveries. The challenge is turning them into pharmaceutical assets.
(the context)
Universities and research centers produce technologies with high therapeutic potential every year. However, without structured development, scientific governance, regulatory strategy, and intellectual protection, most of these discoveries remain confined to academia.
The Aether Platform was created to lead this technological maturation journey and prepare assets for global licensing.
(the platform)
One platform. Two complementary pillars.
The Aether Platform brings together two institutions with distinct, complementary roles, enabling the entire pharmaceutical asset development journey, from research to market preparation.
Aether Global Pharma
Responsible for the platform's business strategy, leading asset development, intellectual property, financial structuring, strategic partnerships, and international licensing.
ICT AetherBio+
Scientific institution responsible for the projects' technological advancement, scientific governance, research coordination, de-risking, and engagement with universities, research centers, and funding agencies.
(our journey)
A platform born within research.
2000
Origins in the pharmaceutical industry
The founder begins her career in quality, industrial production, regulatory affairs, and pharmaceutical development.
2005
Expansion into industrial projects
Work on implementation, validation, industrial development, and strategic management projects in the pharmaceutical sector.
2013
Consolidation of international experience
Participation in technological development projects, technology transfer, and management of highly complex pharmaceutical operations.
2020
Evolution toward building technology assets
Accumulated experience reveals an opportunity: turning science into pharmaceutical assets structured for licensing.
2025
Founding of Aether Global Pharma
A company dedicated to building, developing, and monetizing pharmaceutical assets is born.
2025
Creation of ICT AetherBio+
The platform's scientific arm is established to accelerate the technological maturation of research.
2026
Consolidation of the Aether Platform
Securing strategic projects, federal funding, and scientific partnerships, and expanding operations as an integrated pharmaceutical asset development platform.
People who turn science into pharmaceutical assets.
The Aether Platform brings together professionals with experience in pharmaceutical development, intellectual property, regulatory affairs, business strategy, and technology transfer. Our model integrates scientific experts, executives, and strategic partners to guide assets from discovery to global licensing opportunities.
Meet the team
Let's build the next generation of pharmaceutical assets.
We're looking for researchers, universities, companies, investors, and strategic partners committed to turning excellent science into therapeutic solutions with global impact.